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SUMMARY
Background
A majority of studies investigating the accuracy of ultrasound for
detecting hepatocellular carcinoma (HCC) do not reflect how this test is
used for surveillance vs. diagnosis.
Aim
To determine the performance characteristics of surveillance with ultra-
sound for the detection of HCC, particularly early HCC as defined by
the Milan criteria.
Methods
A systematic literature review using the MEDLINE and SCOPUS databases
yielded six studies that evaluated the accuracy of ultrasound for HCC at
any stage and 13 studies that were specific to early HCC.
Results
Surveillance ultrasound detected the majority of tumours before they
presented clinically, with a pooled sensitivity of 94%. However, ultra-
sound was less effective for detecting early HCC with a sensitivity of
63%. Alpha-fetoprotein provided no additional benefit to ultrasound.
Meta-regression analysis demonstrated a significantly higher sensitivity
for early HCC with ultrasound every 6 months than with annual surveil-
lance. Current studies have limitations such as verification bias and are
of suboptimal quality.
Conclusions
Surveillance with ultrasound demonstrates limited sensitivity for early
HCC, although this may be improved by testing at 6-month intervals.
Currently available evidence evaluating surveillance ultrasound has sig-
nificant limitations and future studies are necessary to determine opti-
mal surveillance methods for early HCC.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most
common tumour worldwide, with an increasing inci-
dence in Europe and the US.1–3 It is currently the third
leading cause of cancer-related deaths worldwide,
resulting in over 500 000 deaths ⁄ year.2–4 Cirrhosis,
particularly when related to viral hepatitis, is the most
notable risk factor for HCC and is found in nearly
80–90% of cases.1, 5 Despite advances in technology
and available treatments, there has been little
improvement in survival with a 5-year survival of 5%
in 1996 compared to 4% in 1985.6, 7
The stage of disease at the time of diagnosis largely
determines the effectiveness of treatment. The treat-
ment of advanced HCC continues to be primarily palli-
ative, with curative options only available for early
HCC. In patients with preserved hepatic function, no
evidence of portal hypertension, and single asymptom-
atic tumours <5 cm in diameter, surgical resection has
provided 5-year survival rates of 70%.8 Similarly, liver
transplantation for tumours meeting the Milan criteria
(one nodule <5 cm or three nodules each <3 cm in
diameter) has a 5-year survival rate of nearly 74%.8–10
In patients with early-stage disease who are not ame-
nable to resection or transplantation, radiofrequency
ablation has demonstrated 5-year survival rates of
37%.8 These survival rates are in stark contrast to the
average survival of <1 year reported for advanced
HCC.11 Unfortunately, less than 30% of patients are
diagnosed early enough to meet criteria for resection
or transplantation.12
Surveillance strives to detect HCC at an early stage
when it is amenable to curative therapy to reduce
mortality.13 Currently, surveillance for HCC is widely
accepted among high-risk populations, most notably
patients with cirrhosis. Current guidelines from the
American Association for the Study of Liver Disease
(AASLD) and the European Association for the Study
of the Liver recommend surveillance of cirrhotic
patients with ultrasound with or without alpha-feto-
protein (AFP) every 6–12 months. Although these tests
have been extensively studied for the purpose of diag-
nosis,14, 15 the results of those studies do not reflect
the performance of these tests in clinical practice. Few
trials have prospectively evaluated the utility of ultra-
sound and AFP as a surveillance test. Given the lack
of a randomized trial of HCC surveillance among
patients with cirrhosis, a meta-analysis is needed to
estimate more precisely the accuracy of ultrasound
and AFP as surveillance tests for HCC. The aim of our
study was to determine the pooled sensitivity, specific-
ity and diagnostic odds ratio (OR) of ultrasound and




We searched the MEDLINE and SCOPUS databases
from database inception through 1 July 2007 with the
following keyword combinations: hepatocellular carci-
noma AND screening, hepatocellular carcinoma AND
surveillance, hepatocellular carcinoma AND cirrhosis
or hepatocellular carcinoma AND ultrasound. Manual
searching of the reference lists from applicable studies
was performed to identify any studies through 1 July
2007 that may have been missed by the electronic
search.
Study selection
Two investigators (A.S. and R.S.) independently
reviewed the publications titles identified by the search
strategy. If the applicability of an article could not be
determined by title or abstract alone, the full text was
reviewed. The articles were independently checked for
possible inclusion and any disagreements were
resolved through consensus with a third reviewer
(M.V.).
Study inclusion and exclusion criteria
Studies were included for analysis if they (i) utilized
ultrasound, with or without concomitant AFP, for HCC
surveillance in cirrhotic patients; (ii) performed the
tests prospectively in a series of patients and (iii)
reported the number of discovered HCC, number of
early HCC and number of missed lesions.
Prospective studies performed among a noncirrhotic
cohort, such as patients with chronic hepatitis, were
excluded from the meta-analysis. If the study cohort
included both patients with cirrhosis and chronic hep-
atitis, only data regarding cirrhotic patients were
included. Studies that evaluated surveillance tech-
niques other than ultrasound, e.g. computed tomogra-
phy (CT) scan or new biomarkers, were excluded. If
multiple techniques were used for surveillance, only
lesions discovered by ultrasound and ⁄ or AFP were
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recorded as true positives; HCC nodules seen only by
other techniques were counted as missed lesions. Stud-
ies using sequential test combinations, such as ultra-
sound testing in patients based on AFP levels, were
excluded; information bias from the initial study could
have unpredictable effects on the ultrasound operating
characteristics. Studies evaluating ultrasound for
screening instead of surveillance were not included in
the analysis. Screening was defined as the one-time
application of the test to detect a previously undiag-
nosed lesion, whereas surveillance was defined as the
repeated use of the test at a set interval over time.
Studies that failed to detail the number of false-nega-
tive results, i.e. patients with missed lesions, were
excluded given that lack of this information precluded
sensitivity calculations. Additional exclusion criteria
included non-English language, nonhuman data, lack
of original data and incomplete reports including
meeting abstracts. If duplicate publications used the
same cohort of patients, the data from the most recent
manuscript were included.
Data extraction
Two reviewers (A.S. and R.S.) independently reviewed
and extracted the required information from eligible
studies using standardized forms. A third investigator
(M.V.) was available to resolve any discrepancies
between the two sets of extracted data. The data
extraction form included the following study design
items: geographical location and date of study,
characteristics and size of study cohort, inclusion and
exclusion criteria, surveillance methods, surveillance
interval, duration of follow-up and ‘gold-standard’
methods for confirmation of HCC. In addition, the
extraction form recorded the following primary data:
number of HCC discovered during surveillance (true
positives), number of false positives, number of missed
lesions (false negatives) and number of true negatives.
The method of tumour detection, i.e. ultrasound or
AFP, was recorded for each tumour. We recorded the
proportion of HCCs discovered at an early stage as
defined by Milan criteria: one nodule <5 cm or three
nodules each <3 cm in diameter, without gross
vascular invasion. Some studies were excluded if they
otherwise defined early-stage disease (e.g. unifocal
lesion <3 cm) and there were insufficient data to deter-
mine the number of patients meeting Milan criteria.
Two independent reviewers (A.S. and R.S.) assessed
the study quality by a modified checklist based upon
the Quality Assessment Tool for Diagnostic Accuracy
(QUADAS) guidelines16 with discrepancies resolved by
a consensus reviewer (M.V.).
Statistical analysis
The first aim of this study was to determine the sensi-
tivity and specificity of surveillance ultrasound to
detect HCC at any stage. The second aim was to deter-
mine the sensitivity of surveillance ultrasound to
detect early HCC and if there is any additional benefit
of concurrently checking AFP. For each individual
study, per-patient sensitivity, per-patient specificity
and diagnostic ORs with 95% confidence intervals
were calculated. Pooled estimates of each calculation
were then computed using STATA 10 (StataCorp, College
Station, TX, USA). Estimates of effect were pooled
using the DerSimonian and Laird method for a random
effects model.
The heterogeneity of diagnostic test parameters was
initially evaluated graphically by examination of for-
est plots and then statistically by the chi-squared test
of heterogeneity and the inconsistency index (I2). A
chi-squared P-value <0.05 or I2 values >50% are
consistent with the possibility of substantial hetero-
geneity.17, 18 Sensitivity analysis, in which one study
is removed at a time from the model, was performed
to determine if there was possible undue influence of
a single study.19 Among the studies assessing surveil-
lance for early HCC, publication bias was initially
evaluated graphically by funnel plot analysis and then
statistically using Begg’s test.20 A symmetric funnel
plot would help rule out the possibility of small stud-
ies that were not published due to unfavourable
results. A summary receiver operator characteristics
curve (SROC curve) was constructed to illustrate the
distribution of sensitivities and specificities.21–23 The
area under the curve (AUC) was computed, with per-
fect tests having an AUC of 1 and poor tests having
an AUC close to 0.5.24
Subset analysis was planned for the detection of
early HCC for predefined subsets of studies based on
(i) use of concurrent surveillance tests; (ii) length of
surveillance interval; (iii) location of study; (iv) date
of study; (v) percentage of viral hepatitis patients; (vi)
percentage of Child’s A cirrhotics; (vii) incidence of
HCC and (vii) length of follow-up. Meta-regression,
using the Knapp–Hartung method for variance estima-
tion,25 was performed to investigate possible sources
of heterogeneity in sensitivity measures across the
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studies. Models were then refitted using a Monte-Carlo




Upon review of the 8826 titles identified by the search
strategies, 192 abstracts were further examined. Sixty-
three publications underwent full-text review to deter-
mine their eligibility for the meta-analysis and 48
were excluded. Thirteen studies were excluded because
they did not use ultrasound, two articles used ultra-
sound but not as a surveillance tool, 10 studies were
not conducted among patients with cirrhosis, nine
studies were retrospective, eight studies were excluded
for lack of original data and eight studies had insuffi-
cient data for extraction. The remaining 13 studies
were selected after meeting all applicable inclusion
criteria (Figure 1). Six studies detailed the number of
false-positive and false-negative lesions and were
selected for the first part of the analysis in which the
sensitivity and specificity of ultrasound to detect HCC
at any stage were assessed (Table 1). All 13 studies
were used in the second part of the analysis in which
the sensitivity of ultrasound with and without AFP to
detect early HCC was assessed (Table 2). Only six of
the 13 studies reported false positives for the detection
of early HCC, thus limiting accurate evaluation of
specificity with regard to early HCC. There was excel-
lent agreement between the two reviewers for both
parts of the analysis (j = 1.0).
Ultrasound for detecting HCC at any stage
Six studies detailed the number of false-positive and
false-negative lesions and were selected for the first
part of the analysis in which the sensitivity and speci-
ficity of ultrasound to detect HCC at any stage were
assessed. The included studies had significant hetero-
geneity (v2 = 12.8, P = 0.02, I2 = 60.8%) and hence
meta-analysis was not initially possible. Inspection of
forest plots suggested that the Caturelli study27 was an
important outlier. The calculated OR (=38 239) from
this study was significantly higher than that of other
included studies and is inconsistent with what is seen
in clinical practice. This could have been related in
part to the higher rate of HCC in this study population,
suggesting that the study population is different from
that in the other studies. We performed sensitivity
analysis and found that omission of the Caturelli study
had a large effect on the overall estimate of the rela-
tive risk. After omission of this study, there was
8826 citations reviewed
192 abstracts reviewed
63 full articles reviewed
13 articles included
6 articles assessed HCC overall
13 articles assessed early HCC
8634 citations not on the topic of
ultrasound and/or AFP as a
surveillance tool for hepatocellular
carcinoma
10 abstracts non-cirrhotic population
35 abstracts did not use surveillance
17 abstracts did not use ultrasound
24 abstracts without original data
9 articles retrospective
2 articles did not use surveillance
13 articles did not use ultrasound
8 articles without original data
8 articles without sufficient data
10 articles non-cirrhotic population
44 abstracts retrospective
Figure 1. Map of the literature
search and selection process.
HCC, hepatocellular carci-
noma; AFP, alpha-fetoprotein.
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significant reduction in the heterogeneity (v2 = 5.8,
P = 0.22, I2 = 30.9%).
Repeat analysis after exclusion of the Caturelli study
demonstrated a pooled sensitivity of 94% (95% CI:
83–98), a pooled specificity of 94% (95% CI: 89–97)
and a pooled diagnostic OR of 232.7 (95% CI: 105.9–
511.2) (Table 3, Figure 2). Using these pooled estimates
for sensitivity and specificity, 82.1% of patients with a
positive ultrasound would have HCC. Sensitivity anal-
ysis with the remaining five studies did not show any
significant change in the relative risk with removal of
any other studies. There did not appear to be any
publication bias by Beggs test (P = 0.71) or funnel plot
analysis. SROC analysis demonstrated an AUC of 0.98
(95% CI: 0.96–0.99) suggesting high diagnostic
accuracy (Figure 2).
Ultrasound for detecting early HCC
All 13 studies were used in the second part of the
analysis in which the sensitivity of ultrasound with
and without AFP to detect early HCC was assessed.
Table 1. Studies evaluating ultrasound for the detection of hepatocellular carcinoma at any stage
First author









Kobayashi33 Japan 95 8.4 50.4 2–3 Histology or angiography
Pateron34 France 118 11.9 35.8 6 Histology or CT
Bolondi42 Italy 313 19.5 56 6 Histology or CT
Caturelli27 Italy 1827 14.7 43.1 4 Histology or AFP >200 with
mass on imaging
Sangiovanni43 Italy 417 26.8 148 6–12 Histology, CT or angiography
Sangiovanni44 Italy 214 31.8 114 6–12 Histology or AFP >200 with
mass on imaging
Pts, patients; HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein.
Table 2. Studies evaluating ultrasound for the detection of early hepatocellular carcinoma
First author









(months) Criteria used to establish diagnosis of HCC
Kobayashi33 Japan 95 4.2 50.4 2–3 Histology or angiography
Arrigoni28 Italy 164 6.7 32.5 4–12 Histology or arteriography
Oka31 Japan 140 19.2 41.1 2–3 CT or arteriography
Pateron34 France 118 2.5 36 6 Histology or CT
Cottone29 Italy 147 17.7 24 6 Histology
Zoli32 Italy 164 18.9 7–77 3–6 Biopsy or CT
Tradati45 Italy 40 5 48 12 Histology or AFP >400 with mass on imaging
Henrion30 Belgium 94 4.3 34 3–6 Histology, CT or MRI
Bolondi42 Italy 313 16 56 6 Histology or CT
Caturelli27 Italy 1599 16.5 43.1 4 Histology or AFP >200 with mass on imaging
Santagostino46 Italy 66 3 72 6–12 Histology, AFP > 400 with mass on
ultrasound, CT or MRI
Sangiovanni43 Italy 417 13.2 148 6–12 Histology, CT or angiography
Sangiovanni44 Italy 214 15.9 114 6–12 Histology or AFP >200 with mass on imaging
Pts, patients; HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; CT, computed tomography; MRI, magnetic resonance
imaging.
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Only six of the 13 studies reported false positives for
the detection of early HCC, thus limiting accurate
evaluation of specificity with regard to early HCC. The
13 studies evaluating early HCC had a significant
degree of heterogeneity (v2 = 195.8, P < 0.001,
I2 = 94%). Inspection of the forest plots confirmed a
large variation in pooled estimates with six studies27–32
having ORs >300 (Figure 3). Sensitivity analysis
suggested that the studies by Caturelli and Sangiovanni
were important outliers with large effects on the overall
Table 3. Performance characteristics of ultrasound for the detection of hepatocellular carcinoma at any stage
First author and study No. pts No. HCC Sensitivity (95% CI) Specificity (95% CI) Odds ratio (95% CI)
Kobayashi33 95 8 0.75 (0.35–0.97) 0.98 (0.92–1.0) 128 (15–1000)
Pateron34 118 14 0.79 (0.49–0.95) 0.96 (0.90–0.99) 91 (18–463)
Bolondi42 313 61 0.93 (0.84–0.98) 0.95 (0.91–0.97) 262 (82–833)
Caturelli27 1599 269 1.0 (0.99–1.0) 0.99 (0.98–0.99) 38 240
Sangiovanni43 417 112 0.98 (0.94–1.0) 0.85 (0.81–0.89) 317 (76–1000)
Sangiovanni44 214 68 0.99 (0.92–1.0) 0.90 (0.84–0.95) 632 (81–1000)
Pooled estimates 2715 412 0.95 (0.89–.98) 0.91 (0.76–0.97) 191.6 (89.2–411.8)
Pooled estimates* 1116 143 0.94 (0.83–.98) 0.94 (0.89–0.97) 232.7 (105.9–511.2)
Pts, patients; HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein.
* Pooled estimates after exclusion of outlier studies (Caturelli et al.27).




















Q = 25.48, df = 4.00, P = 0.0
I2 = 84.30 (71.63–96.98)
Combined
Q = 13.68, df = 4.00, P = 0.0
I2 = 70.76 (43.51–98.02)
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Figure 2. Performance characteristics of ultrasound for the detection of hepatocellular carcinoma (HCC) at any stage:
(a) forest plot for the sensitivity of ultrasound to detect HCC at any stage; (b) forest plot for the specificity of ultrasound
to detect HCC at any stage; (c) forest plot for the odds ratio of ultrasound to detect HCC at any stage; (d) summary
receiver operator curve plot for the detection of HCC at any stage by ultrasound. Q, chi-squared test of heterogeneity;
I2, inconsistency index; AUC, area under the curve.
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estimate of the OR. Omission of the Caturelli study
resulted in substantial improvement in the hetero-
geneity (v2 = 84.6, P < 0.001, I2 = 87%). The OR
(=3849) from the Caturelli study was significantly
higher than that of other included studies, suggesting
marked differences in the underlying patient popu-
lation. Although repeat sensitivity analysis suggested
that the two studies by Sangiovanni continued to be
outliers, omission of these studies did not result in
significant improvement in the degree of heterogeneity
(v2 = 42.4, P < 0.001, I2 = 79%) so they were not
excluded. After exclusion of the Caturelli study, repeat
analysis demonstrated a pooled sensitivity of 63%
(95% CI: 49–76) (Figure 3, Table 4). Although the study
by Oka et al.31 was the only study to include prevalent
tumours, i.e. HCC diagnosed within the first 6 months,
this study was not an outlier on sensitivity analysis or
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Figure 3. Sensitivity of ultrasound with and without afp for the detection of early-stage hepatocellular carcinoma (HCC):
(a) forest plot for the sensitivity of ultrasound to detect early HCC; (b) forest plot for the sensitivity of ultrasound with AFP
to detect early HCC. Q, chi-squared test of heterogeneity; I2, inconsistency index.
Table 4. Sensitivity of ultrasound with or without alpha-fetoprotein for the detection of early-stage HCC
First author








Kobayashi33 95 8 6 0.5 (0.16–0.84) 0.50 (0.16–0.84)
Arrigoni28 164 16 12 0.69 (0.41–0.89) 0.75 (0.48–0.93)
Oka31 140 40 33 0.68 (0.51–0.81) 0.8 (0.64–0.91)
Pateron34 118 14 5 0.23 (0.05–0.54) 0.38 (0.14–0.68)
Cottone29 147 5 4 0.87 (0.69–0.96) 0.87 (0.69–0.96)
Zoli32 164 34 32 0.91 (0.76–0.98) 0.91 (0.76–0.98)
Tradati45 40 6 2 0.33 (0.04–0.78) 0.33 (0.04–0.78)
Henrion30 94 6 6 0.67 (0.22–0.96) 1.0 (0.54–1.0)
Bolondi42 313 61 50 0.82 (0.70–0.91) 0.82 (0.70–0.91)
Caturelli27 1599 269 264 0.98 (0.96–0.99) 0.99 (0.96–0.99)
Santagostino46 66 8 2 0.25 (0.03–0.65) 0.25 (0.03–0.65)
Sangiovanni43 417 112 55 0.50 (0.41–0.60) 0.50 (0.41–0.60)
Sangiovanni44 214 68 34 0.50 (0.38–0.62) 0.50 (0.38–0.62)
Pooled estimates 3113 498 434 0.69 (0.50–0.83) 0.74 (0.56–0.87)
Pooled estimates* 1514 229 170 0.63 (0.49–0.76) 0.69 (0.53–0.81)
Pts, patients; HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein.
* Pooled estimates after exclusion of outlier studies (Caturelli et al.27).
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of prevalent HCC (n = 2) in this study was unlikely
to have a large statistical impact and this study was
not excluded. There did not appear to be any
publication bias by Begg’s test (P = 0.75) or funnel plot
analysis.
Possible causes for heterogeneity in the sensitivity
of ultrasound for the detection of early HCC were then
evaluated by meta-regression. The use of concurrent
tests, e.g. CT scan, accounted for a significant degree
of variation in sensitivity across the included studies
(P = 0.002). The pooled sensitivity for the two studies
with concurrent tests33, 34 was 33.3% (95% CI: 7.7–
58.9), while the pooled sensitivity for studies without
concurrent tests was 64.3% (95% CI: 52.2–76.5). Dif-
ferences in the interval between surveillance examina-
tions also explained heterogeneity in sensitivity
between studies (P = 0.001). Studies with surveillance
intervals of <6 months had a pooled sensitivity of
70.1% (95% CI: 55.6–84.6), while the studies with sur-
veillance intervals between 6 and 12 months had a
pooled sensitivity of 50.1% (95% CI: 40.0–59.2)
(Figure 4). Both the use of concurrent tests and length
of surveillance interval remained statistically signifi-
cant after testing for multiplicity using a Monte-Carlo
permutation test with 10 000 replications. The propor-
tion of patients with Child’s A cirrhosis (P = 0.44) and
duration of follow-up from enrolment (P = 0.26) were
not statistically significant causes of heterogeneity.
There was no significant difference in the sensitivity
of ultrasound between studies conducted in Europe
and those conducted in Asian countries (P = 0.98).
Similarly, there were no differences between studies
conducted before and after 1992 (P = 0.91), suggesting
that advances in technology did not play a major role.
AFP and ultrasound for detecting early HCC
Finally, we explored the additional benefit of AFP in
conjunction with ultrasound for the detection of early
HCC and found that the pooled sensitivity increased to
69% (95% CI: 53–81%; P = 0.65). The forest plot of
the sensitivity of ultrasound and AFP for detecting
early HCC is shown in Figure 3. A wide range of AFP
cut-offs (15–400 ng ⁄ mL) were used to diagnose HCC
in the included studies, although the cut-off level did
not appear to affect the utility of AFP (P = 0.95).
Quality assessment
Using the QUADAS16 checklist for methodological
quality, we found that 12 of the 13 included studies
were limited by verification bias. Only Kobayashi
et al.33 had reference tests, CT scan and infusion hepa-
tic angiography in every patient regardless of ultra-
sound results. Additionally, none of the studies
followed patients for an additional period of time to
confirm that patients without HCC at the end of the
study did not have undetected tumours. In each of the
other 12 studies, no additional tests were performed in
all cirrhotic patients to confirm the absence of HCC.
Study






























Subtotal (I2 = 83.6%, P = 0.000)
Figure 4. Meta-regression using
surveillance intervals for the
sensitivity of ultrasound to
detect early hepatocellular
carcinoma (HCC). Studies with
surveillance at least every
6 months had a significantly
higher sensitivity for early-
stage HCC than studies
performing surveillance on an
annual basis (P = 0.001).
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Kobayashi was also the only study in which reviewers
of the reference standard were clearly blinded to
results of the index ultrasound. The other 12 studies
relied primarily on ultrasound-guided biopsy to con-
firm the diagnosis of HCC.
DISCUSSION
Our study is the first meta-analysis to evaluate ultra-
sound with or without AFP as a surveillance tool for
early HCC in cirrhotic patients. We demonstrated that
surveillance programmes with ultrasound are highly
accurate for HCC at any stage, with a pooled sensitiv-
ity of 94% and a pooled specificity of 94%. However,
the detection of early HCC is of greater importance for
surveillance to be successful. Our study demonstrated
that ultrasound only has a pooled sensitivity of 63%
for those with early HCC. Meta-regression analysis
demonstrated a significantly higher sensitivity for
early HCC with an ultrasound every 6 months than
with annual surveillance (P = 0.001).
Although a systematic review has been previously
performed on the efficacy of ultrasound for the diag-
nosis of HCC,15 there are several significant differences
from our meta-analysis. First, we only included studies
that used ultrasound as a surveillance tool in a pro-
spective manner, whereas previous studies assessed
ultrasound as a one-time diagnostic tool. This is an
important distinction given that ultrasound is most
commonly used as a surveillance tool in clinical prac-
tice. Second, our analysis specifically evaluated the
sensitivity of ultrasound for early HCC. Once again,
this is clinically relevant as curative measures are only
available for early HCC, making detection of tumours
at this stage essential during surveillance.
As commonly discovered in meta-analyses of diag-
nostic tests,35 we found a moderate degree of hetero-
geneity for the sensitivity of surveillance ultrasound to
detect HCC. This heterogeneity can be related to vari-
ability in diagnostic thresholds, study populations, test
equipment or methods, study quality or a combination
of these factors.36 We were unable to explore some
possible aetiologies for heterogeneity including differ-
ences in body habitus, operator skill or experience and
inter-operator reliability due to limited available infor-
mation. In our meta-analysis, we found the use of
concurrent tests with ultrasound was able to explain a
significant degree of heterogeneity in the pooled sensi-
tivity estimate for early HCC. The pooled sensitivity
for the two studies with concomitant tests was 33.3%,
which was significantly lower than the sensitivity of
64.3% in the studies without concurrent tests
(P = 0.002). In these latter studies, it is likely that
some tumours were never detected by ultrasound and
AFP during the follow-up period. Therefore, these
reported sensitivities may be falsely high and our
pooled sensitivity of 63% for early HCC may overesti-
mate ultrasound’s true performance characteristics
during surveillance.
There has been considerable debate regarding the
additional benefit of AFP to ultrasound during surveil-
lance as well as the optimal surveillance interval.37
We demonstrated that the addition of AFP to ultra-
sound does not substantially improve the sensitivity of
surveillance for early HCC, independent of the cut-off
level used. Although the pooled sensitivity for early
HCC minimally increased from 63% to 69%, this was
not statistically significant (P = 0.65). This finding is
consistent with the AASLD practice guidelines, which
suggest that AFP is not an adequate screening test, but
has a role in the diagnosis of HCC when >200 ng ⁄ mL
in the setting of a mass on imaging.38
Conversely, variation in surveillance intervals
resulted in significant differences in sensitivity for
early HCC. The pooled sensitivity of the studies with
surveillance at least every 6 months had a pooled sen-
sitivity of 70.1%, which was significantly better than
the sensitivity of 50.1% in studies performing surveil-
lance on an annual basis (P = 0.001). Our meta-analy-
sis suggests that surveillance with an ultrasound every
6 months is currently the best interval for detecting
early HCC among patients with cirrhosis.
While some studies have proposed that CT or mag-
netic resonance imaging may be more sensitive as
alternative imaging studies for the detection of HCC,
they have not been adequately studied as surveillance
tests or with regard to early HCC.15 Additionally, the
increased cost and potential adverse effects such as
radiation exposure limit their utility in surveillance.39
There have been promising tumour biomarkers, includ-
ing des-gamma carboxy-prothrombin and the lens
culinaris-agglutinin reactive fraction of AFP (APF-
L3%), but there is insufficient evidence for their use in
clinical practice.40, 41 Overall, more studies are needed
to find novel surveillance tests to improve the detec-
tion of HCC at stages where curative interventions can
be applied.
Although the included studies are the best data cur-
rently available, the primary limitations of our meta-
analysis are the biases observed in these studies. On
META-ANALYSIS : HEPATOCELLULAR CARCINOMA SURVEILLANCE 45
Aliment Pharmacol Ther 30, 37–47
ª 2009 Blackwell Publishing Ltd
quality assessment, verification bias was a significant
concern in all but one study. Only Kobayashi et al.33
performed concurrent imaging that can serve as a ref-
erence standard in all patients, whereas all other stud-
ies performed a ‘gold standard’ reference test only in
patients with a positive ultrasound or AFP. Similarly,
none of the studies followed patients for an additional
period of time to confirm that patients without HCC at
the end of the study did not have any undetected
tumours. In these studies, the calculated sensitivity for
ultrasound may have been subsequently falsely ele-
vated. These limitations are important and suggest that
the sensitivity of ultrasound for early HCC is 63% at
best and may in fact be significantly worse.
Other than the biases of the individual studies,
another limitation of our meta-analysis is that we only
evaluated surveillance in patients with cirrhosis and
our results may not be generalizable to other popula-
tions undergoing HCC surveillance, such as patients
with hepatitis B. Additionally, most of the studies were
conducted in experienced liver centres in Europe and
Asia; the performance of ultrasound may be worse in
an American cohort in which obesity can further limit
its sensitivity and many ultrasounds are performed
outside high-volume medical centres by technicians
instead of radiologists. Finally, our meta-analysis only
evaluated the efficacy of ultrasound to detect early
HCC given the lack of prospective trials evaluating the
effect of surveillance on outcomes such as overall sur-
vival. Despite these limitations, this was the first meta-
analysis evaluating ultrasound and AFP as surveillance
tools for early-stage HCC, rather than single-applica-
tion diagnostic tests. More importantly, this is the first
compilation of studies specifically evaluating the effi-
cacy of surveillance to detect early HCC.
In summary, ultrasound demonstrates a limited sen-
sitivity of 63% but is currently the best surveillance
tool for early-stage HCC among patients with cirrhosis.
The addition of AFP to ultrasound is of minimal bene-
fit, whereas performing ultrasound every 6 months
instead of annually significantly improves sensitivity
for early HCC to 70%. Unfortunately, existing studies
suffer from significant limitations that include verifi-
cation bias, unknown efficacy of ultrasonography in
less-experienced centres and questionable generaliz-
ability of these results to American patients with cir-
rhosis. Further studies should be performed to
overcome these limitations as well as determine if the
addition of novel biomarkers can help improve the
detection of early HCC.
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